, Tracking Stock Market Picks
Enter Symbol:
Rating: AEGR
Hold $26
down 77.00 %

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) downgraded to Hold with price target $26 by Deutsche Bank

Friday,  Oct 31, 2014  1:25 PM ET by Dave Ficere

Deutsche Bank downgraded Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) to Hold with price target $26. Previously Deutsche Bank rated Buy with price target $115 Aegerion Pharmaceuticals,
Inc. (NASDAQ: AEGR) on 11/13/2013, when the stock price was $82.81. Since then, Aegerion Pharmaceuticals, Inc.'s stock price has lost 77% as of 10/31/2014's recent price of $19.26.
If you would have followed the previous Deutsche Bank's recommendation on AEGR, you would have lost 77% of your investment in 352 days.

Aegerion Pharmaceuticals, Inc. (Aegerion) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat severe lipid disorders. Its lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor (MTP-I), which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. The Company is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia (HoFH). HoFH is a genetic lipid disorder caused by defects in both copies of the low-density lipoprotein (LDL) receptor genes, resulting in impaired or total loss of function in the LDL receptor.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy